Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study

European Heart Journal

Volumn 38, Issue 7, 2017, Pages 516-523

  Karakas, Mahir ^a,b   Schulte, Christian ^a   Appelbaum, Sebastian ^a,b   Ojeda, Francisco ^a   Lackner, Karl J ^b,c   Münzel, Thomas ^b,c   Schnabel, Renate B ^a,b   Blankenberg, Stefan ^a,b   Zeller, Tanja ^a,b  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Biomarker; Coronary artery disease; MicroRNA; Prognosis

Indexed keywords

MICRORNA; MICRORNA 132; MICRORNA 140 3P; MICRORNA 142 5P; MICRORNA 150; MICRORNA 186; MICRORNA 19A; MICRORNA 19B; MICRORNA 210; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CIRCULATING MICRORNA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICRORNA BLOOD LEVEL; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; CLINICAL TRIAL; EVALUATION STUDY; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; RISK ASSESSMENT; SECONDARY PREVENTION;

AGED; BIOMARKERS; CIRCULATING MICRORNA; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SECONDARY PREVENTION;

EID: 85016194428     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw250     Document Type: Article

References (20)

1. Wijeysundera HC, Machado M, Farahati F,Wang X, WittemanW, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O'Flaherty M, Krahn M, Capewell S. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. J Am Med Assoc 2010;303:1841-1847.
2. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald E. Application of the TIMI risk score for ST elevation MI in the National Registry of Myocardial Infarction 3. J Am Med Assoc 2001;286 :1356-1359.
3. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, Buysschaert I, Lambrechts D, Van de Werf F. Underestimated and underrecognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010;31:2755-2764.
4. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KA, GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post-discharge death in an international registry. J Am Med Assoc 2004;291:2727-2733.
5. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012;110:483-495.
6. Zeller T, Keller T, Ojeda F, Reichlin T, Twerenbold R, Tzikas S, Wild PS, Reiter M, Czyz E, Lackner KJ, Munzel T, Mueller C, Blankenberg S. Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J 2014;35:2106-2114.
7. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ, AtheroGene Investigators. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003;349:1605-1613.
8. Schnabel R, Messow CM, Lubos E, Espinola-Klein C, Rupprecht HJ, Bickel C, Sinning C, Tzikas S, Keller T, Genth-Zotz S, Lackner KJ, Münzel TF, Blankenberg S. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 2008;29:649-657.
9. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010;107: 677-684.
10. Brase JC, Wuttig D, Kuner R, Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010;9:306.
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B (Methodological) 1995;57: 289-300.
12. Uno H, Cai T, Pencina MJ, D'Agostino RB,Wei LJ. On the c-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 2011;30:1105-1117.
13. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
14. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, Corsten MF, Schroen B, Lair ML, Heymans S,Wagner DR. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 2012;58:559-567.
15. Ivan M, Harris AL, Martelli F, Kulshreshtha R. Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med 2008;12:1426-1431.
16. Corn PG. Hypoxic regulation of miR-210: shrinking targets expand HIF-1's influence. Cancer Biol Ther 2008;7:265-267.
17. Huang X, Zuo J. Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response. Acta Biochim Biophys Sin 2014;46:220-232.
18. Dang K, Myers KA. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci 2015;16:6353-6372.
19. Wu F, Yang Z, Li G. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun 2009;386:549-553.
20. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S, Mayr M. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012;60:290-299.